Posted on

30% less opioid use

Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample

A recent survey of 200,000+ people found that those who have used psilocybin at least once are 30% less likely to have opioid use disorder. However, LSD, mescaline, and peyote use did not seem to have an impact on opioid use. Addiction is linked with abnormal serotonin neurotransmission. Since psilocybin targets the serotonin system, it may help protect against opioid addiction.

Learn more with Chloe Deutscher on TikTok

PDF of article

Posted on

Peyote, but ✨sustainable✨

Wellbeing Digital Sciences’ Subsidiary KGK Science Engaged by Lophos Pharmaceuticals for Novel Peyote Study

Peyote has the longest documented use of any psychedelic, yet we don’t see many companies researching its properties.

That’s because the psychedelic cactus is endangered – the 13-year growth cycle can’t keep up with the rate of harvesting.

Lophos Pharmaceuticals is developing a sustainable cultivation technique that could reduce the long growth cycle to just 3 years, preserving the species and accelerating research.

The CEO of Lophos says that peyote could help treat obesity, addiction, anxiety, and depression, with a strong potential for microdosing. 

PDF of article 1

PDF of article 2

Posted on

Wellbeing Digital Sciences’ Subsidiary KGK Science Engaged by Lophos Pharmaceuticals for Novel Peyote Study

Wellbeing Digital Sciences’ Subsidiary KGK Science Engaged by Lophos Pharmaceuticals for Novel Peyote Study

The Company’s Wholly Owned Contract Research Organization has Been  Engaged by Lophos Pharmaceuticals to Evaluate a Path to Market for  Sustainably Grown, Peyote-Derived Natural Health Products 

Vancouver, British Columbia, March 21, 2022 / Globe Newswire / – Wellbeing Digital Sciences Inc.  (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based  healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital  therapeutics and contract research, is pleased to announce that its wholly owned subsidiary, KGK Science  Inc. (“KGK”) has been engaged by Lophos Pharmaceuticals Inc. (“Lophos”) to evaluate a path to market  for sustainably grown, peyote-derived natural health products (“NHPs”). Lophos is a Canadian psychedelic  research company focused on cultivation and drug development.  

Peyote has legal status in Canada, but mescaline – the drug derived from the plant– remains a Schedule 3  controlled substance. With a focus on NHPs, potential paths to market will be evaluated based on the safety  and sanitary requirements, quality specifications for peyote-derived inputs, and permissible label claims for  packaging and sales.  

Management Commentary  

“Lophos is currently exploring the potential benefits of a peyote-derived natural health product with the  support of KGK Science. There are challenges to growing peyote, and the thirteen-year-long natural  regrowth cycle is a major threat to the endangered plant. At Lophos, we are researching accelerated,  responsible cultivation techniques for reducing the long growth cycle. The goal is to provide our partners  with therapeutic peyote derivatives, grown in a sustainable manner that are beneficial to the plant itself, and  respectful integrations of traditional medicinal plants,” said Claire Stawnyczy, Founder and CEO of  Lophos.  

“We are very excited to engage with Lophos. Peyote and mescaline in general are currently  underrepresented in the psychedelic medicine sector, given their traditional medicinal uses. Lophos  provides a critically important sustainable supply of cacti to the market. We plan to utilize our expertise in  natural health products to aid Lophos in bringing to market, innovative and safe products for the Canadian  consumer,” added Najla Guthrie, President and CEO of KGK.

ABOUT LOPHOS  

Lophos Pharmaceuticals Inc. is a biosciences company that specializes in Peyote research, cultivation,  preservation, and drug development. We develop novel therapies and natural health treatments that aim to  restore and improve the quality of life for patients. Through advanced cultivation and harvesting techniques,  Lophos will provide our partners with medical grade inputs and our patients with access to safe and effective  mescaline-based therapeutics.  

For more information please contact:  

Alex Krause – Cushion Communications Inc.  

alexkrause.pr@gmail.com 

ABOUT KGK SCIENCE 

Founded in 1997, KGK is a leading North American contract research organization based in London,  Ontario that primarily provides high-quality clinical research trials with a focus on the nutraceutical,  cannabis and emerging psychedelic industries. The business has successfully helped hundreds of companies  with custom designed clinical trials and claim substantiation strategies to move products into global  markets. KGK’s other existing service lines include expert regulatory support and compliance solutions,  participant recruitment, research support services and consulting services. On an approximate basis, the  business to date has produced 150 publications, executed over 400 clinical trials across more than 40  indications, amassed 25,000 participants in its database and collected 10 million data points.  

ABOUT WELLBEING DIGITAL SCIENCES 

Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare  company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and  contract research. Its mission is supported by a network of North American clinics that provide ketamine assisted therapies and other types of treatment to patients as well as through a contract research organization  that offers clinical trials services to clients pursuing drug development. In essence, the company exists to  make breakthrough treatments more accessible and to offer patients transformational experiences.  

On behalf of:  

WELLBEING DIGITAL SCIENCES INC. 

“Adam Deffett”  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-746-6351  

Email: ir@wellbeingdigital.co  

Web: www.wellbeingdigital.co 

Twitter: @Wellbeing_IR  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding  the Company’s business, assets or investments, as well other statements that are not historical facts. Readers 

are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that  the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking  statements involve numerous assumptions, known and unknown risks and uncertainties, both general and  specific, that contribute to the possibility that the predictions, forecasts, projections and other forward 

looking statements will not occur, which may cause actual performance and results in future periods to  differ materially from any estimates or projections of future performance or results expressed or implied by  such forward-looking statements. These assumptions, risks and uncertainties include, among other things,  the state of the economy in general and capital markets in particular, investor interest in the business and  prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release.  Except as required by law, the Company disclaims any intention and assumes no obligation to update or  revise any forward-looking statements, whether as a result of new information, future events or otherwise,  except as required by applicable securities law. Additionally, the Company undertakes no obligation to  comment on the expectations of, or statements made, by third parties in respect of the matters discussed  above.  

Posted on

Way2Grow (W2G) Biopharma Corp. Receives Health Canada Approval Notice for Construction of a Controlled Substances Dealer’s Licence Level 8 Psychedelic Secure Environ and Psilocybin Production Campus

Way2Grow (W2G) Biopharma Corp. Receives Health Canada Approval Notice for Construction of a Controlled Substances Dealer’s Licence Level 8 Psychedelic Secure Environ and Psilocybin Production Campus

OSOYOOS, British Columbia, Nov. 17, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Way2Grow Biopharma Corp. (“W2G” or the “Company”), a privately held therapeutic corporation existing under the laws of British Columbia, is pleased to announce approval of a Health Canada Dealer’s Licence Application, in which Health Canada issued notice to W2G to complete the construction of a Level 8 Secure Environ and Psilocybin Production Campus. A Health Canada Dealer Licence and production facility will allow W2G to procure psychedelics as well as propagate, cultivate, harvest and sell psychedelics to pharmacies, clinics and other licenced research facilities for allowable research purposes pursuant to the Controlled Drugs and Substances Act (the “CDSA”).

Licensing

W2G is pioneering a comprehensive Life Science Therapeutic Production Campus with the goal of researching, advancing and manufacturing life science therapeutics. W2G’s Therapeutic Production Campus supports small room, closed-loop, evidence-based therapeutic research and production. The Company’s pure cultivation approach is rooted in science, is empirically based, organically grown and evidence driven. W2G’s approach uses standardized tissue culture and micropropagation to cultivate and extract pure organic cannabis and psychedelic therapeutics. Completion of the Level 8 Controlled Substances Dealer’s Licence will allow W2G to cultivate, extract and store up to $30 million in value of psychedelics compounds, including psilocybin/psilocin (magic mushrooms), N, N-Dimethyltryptamine (DMT), Ololiuqui (Morning Glory), mescaline and peyote.

W2G will be the first comprehensive Life Science Therapeutic Production Campus specializing in psychedelic and cannabis production, micropropagation, organic cultivation, processing and therapeutic manufacturing in North America.  Approval of the Controlled Substances Dealer’s Licence allows W2G to procure controlled substances by synthesis, propagation, cultivation and harvesting of psychedelic substances. W2G will be permitted to sell psychedelic compounds to other licenced dealers, authorized hospitals, research facilities and academic institutions until such time that psychedelics are prescribed by authorized physicians.

To fulfill W2G’s innovative research plans in psychedelic formulations, the Company’s plans include EU-GMP-compliant facility construction to allow for the import and export of psychedelics therapeutics to expand evidence-based psychedelics research through global partnerships. W2G’s research plans include improving breeding programs, standardizing psilocybin production, and the examination of psychedelics’ combinative efficacy on treating certain health conditions.

W2G’s cultivation relies on a small, closed room approach to growing consistent organic medical psilocybin. Each W2G cultivar or spore starts with a consistent germplasm developed though natural breeding and tissue culture. The future of W2G germplasm development will integrate the use of advanced genomic and genetic engineering to produce novel biotechnologies. Each cultivation room operates under specific growing conditions to maintain optimal production and consistent quality of medicinal compounds.

W2G has pioneered a new and strategic comprehensive Life Science Therapeutic Production Campus by combining its expertise in organic cultivation technology with an experienced genetic advancement team, innovative pharmaceutical research plans and intellectual property development, coupled with the highest level of security.

“We are excited to enter this next phase of life science therapeutics, and we believe this unique combination will lead to the highest-quality targeted organic therapeutic products. As we enter this next phase of our company’s evolution, we will focus on building strategic partnerships to help disseminate our psychedelics research and to expand our distribution,” stated W2G CEO Jamie Filipuzzi.

About W2G

W2G is a privately held therapeutic company in the life science industry. W2G began with a vision to help patients gain better access to high-quality, consistent, organic therapeutics. To achieve this vision, W2G has developed a consistent growth plan using tissue culture and molecular biology. These methods allow for the standardization of the procedures used to ensure quality and consistency of W2G’s therapeutics.

W2G’s extensive research and intellectual property approach are focused on the development of several new plant-based cultivation techniques, hybrid cultivar development, genetic profiling and tissue culture. By developing a molecular breeding and genetics program, we can identify new bioactive compounds to determine interaction with specific genes responsible for chronic diseases.

W2G is located in Osoyoos, British Columbia, and is federally regulated in Canada under the Cannabis Act (S.C. 2018, c. 16) and the Cannabis Regulations (SOR/2018-144)).

FORWARD-LOOKING STATEMENTS

This news release may contain “forward-looking statements.” These statements relate to future events or future performance of Way2Grow. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future, including words or phrases such as “anticipate,” “may,” “will,” “might,” “should,” “could,” “can,” “intend,” “expect,” “believe,” “plan,” “project,” “continue” or similar expressions that suggest future outcomes or the negative thereof or similar variations. Such forward-looking statements include, but are not limited to, statements concerning W2G’s research, development and expansion plans, including its Health Canada application for the Dealer Licence and Section 56 Exemption, and the potential results from such Licensing.

Forward-looking statements are based on management’s current expectations and may materially differ from actual results. Further, such forward-looking statements are subject to risks and uncertainties that could negatively affect our business, operating results and financial condition, including, without limitation, risks arising from a delay in Licensing and financing risks. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact Information:

JJ Filipuzzi, Investor Relations
Phone: (403) 554-5973
Email: info@w2g.ca
Website:  www.w2g.ca

Wire Service Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com

Posted on

Seattle becomes the largest US city to decriminalize

Seattle Becomes Largest U.S. City To Decriminalize Psychedelics

With a unanimous vote, a new legislation was passed to decriminalize the possession, cultivation, and sharing of psychedelic mushrooms, ayahuasca, ibogaine and non-peyote-derived mescaline.

Peyote was intentionally excluded from the measure, as it’s in danger of extinction due to the increase in illegal harvesting. In fact, Santa Cruz recently removed peyote and other mescaline-containing cacti from the city’s decriminalization policy after pushback from Indigenous groups that consider the entheogens to be sacred.

PDF of article 1

PDF of article 2